INTENDED USE

The DG Gel 8 A/B/D card is for the determination of human A, B and D antigens on the surface of red blood cells of two separate blood samples.

For use with the DG Gel System.

For in vitro diagnostic use.

SUMMARY AND EXPLANATION

The ABO system was the first human blood group system discovered by Landsteiner in 1900 and is still the most important in transfusion practice. The ABO system is defined by the presence or absence of the A and/or B antigens on human red blood cells and by the presence of antibodies in the plasma or serum corresponding to the antigen or antigens missing in the red blood cells. In the field of transfusion medicine, after A and B antigens, the most important blood group antigen is the D antigen from the Rh blood group system. The determination of RhD is defined by the presence or absence of the D antigen in the red blood cells. The anti-A, anti-B and anti-D reagents contained in the DG Gel 8 A/B/D card are used to perform the ABO and RhD blood group typing in two separate samples.

PRINCIPLE OF THE TEST

The principle of the test is based on the gel technique described by Yves Lapierre in 1985 for detecting red blood cell agglutination reactions. The DG Gel 8 plastic cards are composed of eight microtubes. Each microtube is made of a chamber, also known as incubator sample, at the top of a long and narrow microtube, referred to as the column. Buffered gel solution containing specific antibody (anti-A, anti-B, and anti-D) has been prefilled into the microtube of the plastic card. The agglutination occurs when the red blood cell antigens react with the corresponding antibodies, present in the gel solution or in the serum or plasma sample (in the case of reverse grouping test). The gel column acts as a filter that traps agglutinated red blood cells as they pass through the gel column during the centrifugation of the card. The gel column separates agglutinated red blood cells from non-agglutinated red blood cells based on size. Any agglutinated red blood cells are captured at the top of or along the gel column, and non-agglutinated red blood cells reach the bottom of the microtube forming a pellet.

REAGENTS

Observable indications

Note: Inspect the condition of the cards before use (see Warnings and Precautions).

Cards with an alteration or change in color, trapped bubbles in the gel, cracked gel or gel with fissures, drying gel, presence of other artifacts, and opened or damaged seals may indicate an alteration of the product.
Material provided

Note: All microtubes contain sodium azide (NaN₃) as a preservative at a final concentration of 0.09%.

Each microtube of the DG Gel 8 A/B/D card contains a gel in buffered medium with preservative. All microtubes contain also antibody reagents except the fourth and the eighth that have only the buffered medium. The different microtubes are identified on the front label of the card.

Microtubes A: monoclonal antibody anti-A. IgM antibody of murine origin, clone DAM-1.

Microtubes B: monoclonal antibody anti-B. IgM antibody of murine origin, clone 9621A8. This clone does not react with acquired B cells.

Microtubes D: monoclonal antibody anti-D. IgM antibody of human origin, clone P3x61. This clone detects weak and partial D variants and does not detect partial DVI.

Microtubes Ctl.: buffered solution without antibodies (control microtube).

Clones 9621A8 and P3x61 are produced using intermediate products produced for Diagnostic Grifols S.A. in a shared manufacturing agreement with DIAGAST, Parc Eurasante, 251 av. Eugene Avinee-BP9, 59374 Loos Cedex France; US License Number 1744.

Clone DAM-1 is produced using intermediate products produced for Diagnostic Grifols S.A. in a shared manufacturing agreement with ALBA BIOSCIENCE, Ellen’s Glen Road, Edinburgh, EH17 7QT United Kingdom; US License Number 1807.

Reagent preparation

DG Gel 8 A/B/D cards are supplied as ready to use. The gel cards and samples to be tested should be brought to room temperature (18-25 ºC) before testing.

Material required but not provided

- Automatic pipettes of 10 μL, 50 μL and 1 mL.
- Disposable pipette tips.
- Glass or plastic test tubes.
- Grifols Diluent.
- DG SPIN centrifuge.

Storage and Stability

- Do not use beyond the expiration date.
- Store upright (as indicated by the two arrows on the outer packaging) with seal intact at 2-25ºC.
- Do not freeze.
- Do not expose cards to excessive heat.

Warnings and Precautions

- The results by themselves alone are not a clinical diagnosis. Evaluate the results together with the patient’s clinical information and other data.
- If you observe microbiological contamination, alterations or changes in color, or other artifacts do not use the card.
- If you observe trapped bubbles in the gel, cracked gel or gel with fissures, drying gel, or gel without a visible fine line of supernatant do not use the card.
- Do not use the card if opened or if the aluminum film seal is damaged.
- If you identify incorrect temperature conditions during storage or shipment, do not use the cards.
- If you identify improper storage or shipping conditions that results in dispersed drops observed at the top of the microtube, the card should be centrifuged with the DG SPIN before use. If after one centrifugation with the DG SPIN the drops do not descend, do not use the card.
- The product should only be used by qualified personnel.
- The use of volumes and/or red blood cell suspensions in concentrations other than those indicated in the method, may modify the reaction and lead to incorrect test results, i.e., false positive or false negative results.
- The use of diluents other than Grifols Diluent for the red blood cell suspension may modify the reaction and lead to incorrect test results.
- Do not use a centrifuge other than the DG SPIN centrifuge.
- The reagents of the DG Gel 8 A/B/D card of human monoclonal origin are manufactured using materials that have been tested and found non-reactive for the HBs antigen, and for anti-HIV and anti-HCV antibodies. However, there is no known procedure to ensure that products of human origin will not transmit infectious agents. Human blood products and samples should be handled as if they were potentially capable of transmitting infectious diseases.
- All products with animal derived material, and human blood products and samples should be handled as if they were potentially capable of transmitting infectious diseases.
- Once used, dispose the product in containers for biological waste, according to local, state and national regulations.
- If you have any questions or need further information on the use of this product, consult the authorized distributor.

**SPECIMEN COLLECTION AND PREPARATION**

Blood samples collected in EDTA, sodium citrate or sodium heparin should be used. The collection, separation and handling of the blood should be performed by qualified technical personnel according to current standards, and following the instructions of the manufacturer of the materials used for collecting the sample.

Do not use grossly hemolyzed, cloudy or contaminated samples. Use the red blood cells collected for the determination of the antigens of the ABO and RhD system. If necessary, samples stored at 2-8 °C can be used up to 72 hours after collection. Red blood cells from bags collected in ACD, CPD, CPDA-1, CP2D AS-1 (Adsol) or AS-3 can also be used up to 7 days after the expiration date indicated on the label of the bag, if stored at 2-8 °C. If red blood cells from the bag segment are used, it is recommended that these be washed with physiological saline solution before preparing the suspension. Do not use if clots or hemolysis are observed. For the determination of the ABO reverse group use serum or plasma.

**PROCEDURE**

1. Allow DG Gel 8 A/B/D cards, additional reagents and the samples to reach room temperature (18-25 °C).
2. Inspect the condition of the cards before use (see Warnings and Precautions).
3. Identify the cards to be used and the samples to be tested.
4. Prepare a 5% red blood cell suspension in Grifols Diluent (50 μL of packed red blood cells in 1 mL of Grifols Diluent).

5. Remove the foil seal from the complete DG Gel 8 card or from the individual microtubes to be used for testing. Carefully peel off the aluminum film to prevent cross-contamination of the microtube contents among them.

6. Ensure the re-suspension of the red blood cells before use.

7. Add 10 μL of the 5% red blood cell suspension into each of the A/B/D/Ctl microtubes.
   **Note:** Carefully dispense the red blood cell suspension avoiding contact of the pipette tip with the wall or the contents of the microtubes to prevent carryover.

8. Centrifuge the gel card in the DG SPIN centrifuge.

9. After centrifugation, remove the gel card from the centrifuge and read the results.

**RESULTS**

Report results as an agglutination grade, absence of agglutination or hemolysis.

**Negative results:** no agglutination and no hemolysis of red blood cells is visible in the microtube. In a negative result the red blood cells are located in the bottom of the gel column.

**Positive results:** agglutination and/or hemolysis of the red blood cells is visible in the microtube. In a positive result the agglutinated red blood cells may remain throughout the gel column showing different reaction grades (see Reaction Grades and Figure 1 for a picture of example of reaction grades). Some positive reactions may also form a pellet in the bottom of the microtube. A very weak reaction may indicate a very weak or partial expression of the ABO and RhD antigens.

**Notes:**
1. Some fibrin, particulates or other artifacts may trap red blood cells at the top of the gel columns erroneously leading to an abnormal result (see limitation number 7).
2. Occasionally red blood cell retention in the incubation chamber may occur with positive 4+ samples, without interfering in the result interpretation.

**Reaction Grades:**

<table>
<thead>
<tr>
<th>Negative</th>
<th>0</th>
<th>Well-defined pellet of non-agglutinated red blood cells at the bottom of the gel column and no visible agglutinated cells in the rest of the gel column.</th>
</tr>
</thead>
<tbody>
<tr>
<td>w+</td>
<td>Barely visible small-sized clumps of agglutinated cells in the lower part of the gel column and a pellet of unagglutinated cells at the bottom.</td>
<td></td>
</tr>
<tr>
<td>1+</td>
<td>Some small-sized clumps of agglutinated cells most frequently in the lower half of the gel column. A small pellet may also be observed at the bottom of the gel column.</td>
<td></td>
</tr>
<tr>
<td>2+</td>
<td>Small or medium-sized clumps of agglutinated cells throughout the gel column. A few unagglutinated cells may be visible at the bottom of the gel column.</td>
<td></td>
</tr>
<tr>
<td>3+</td>
<td>Medium-sized clumps of agglutinated cells in the upper half of the gel column.</td>
<td></td>
</tr>
<tr>
<td>4+</td>
<td>A well-defined band of agglutinated red blood cells in the top part gel column. A few agglutinated cells may be visible below the band.</td>
<td></td>
</tr>
<tr>
<td>mf</td>
<td>Mixed-field. A band of red blood cells at the top part of the gel or dispersed throughout the gel column, and a pellet in the bottom as a negative result.</td>
<td></td>
</tr>
</tbody>
</table>
Hemolysis in the microtube with very few or no red blood cells in the gel column. Report if hemolysis is present in the microtube but not in the sample.

Figure 1. Picture of an example of reaction grades.

**Stability of the results**

After centrifuging the cards it is recommended that the results be read immediately. Do not leave processed cards in a horizontal position. If necessary, a delayed reading can be performed up to 24 hours after processing the cards if they are kept in an upright position, refrigerated (2-8 °C) and sealed with a laboratory covering film to avoid evaporation of the supernatant.

**QUALITY CONTROL**

Include positive and negative controls with testing on each day of use. If an unexpected control result is obtained, a complete assessment of the instrument, reagents and material used should be made.

**Interpretation of the results**

**ABO system.** The expected reaction with microtubes A and B, and its interpretation are shown in the following table (+ = positive, and 0 = negative).

<table>
<thead>
<tr>
<th>ABO Forward group</th>
<th>Interpretation ABO group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microtube A</td>
<td>Microtube B</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>+</td>
<td>0</td>
</tr>
<tr>
<td>0</td>
<td>+</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**D antigen (Rh system).** A positive result in the corresponding microtube indicates the presence of antigen D (Rh system).

**Notes:**

1. The acronym “Ctl.” means Control.
2. The Ctl. microtube should be negative. If it is positive, due to the formation of rouleaux, to strong cold autoagglutinins or other causes, invalidate the test. Repeat the determination after washing the red blood cells with physiological saline solution and preparing a new suspension of the washed red blood cells. If the Ctl. microtube of the repeat test is negative, the results of the test can be interpreted; if it is positive, invalidate the test.

3. The ABO and RhD group obtained should be verified comparing the result obtained with a previously typed sample. If a previously typed sample is not available, it is recommended to determine the reverse group. Forward (cell grouping) and reverse (serum grouping) discrepancies should be investigated before releasing the result.

4. To ensure detection of weak and partial D variants or if verification of D negative status is required, other reagents and techniques (e.g. indirect antiglobulin testing) which may detect different weak and partial D variants should be used.

5. Precaution should be taken in the interpretation of mixed-field events. Not all mixed-cell situations are detected. Additional information on patient history and additional testing will be necessary for resolution. Transfused patients or those subjected to bone marrow transplant may present images of mixed-field. Mixed-field is also observed in some ABO subgroups (A3), in blood group chimerism in fraternal twins, and in the very rare case of mosaicism arising from dispermmy.

6. The observation of complete or partial hemolysis (pinkish supernatant and/or gel column) in microtubes should be interpreted as a positive result, after verifying that it is not due to a problem of collection and/or handling of the sample.

LIMITATIONS OF THE PROCEDURE

1. Grossly hemolyzed, cloudy or contaminated samples or samples with presence of a clot, may cause false positive or false negative results.

2. Aged or hemolyzed specimens may cause weaker reactions compared to those obtained with a fresh sample.

3. Red blood cells from individuals with A or B variants may present a weak expression of the antigens, and may not be detected. These weak antigens may be better detected using reagent anti-AB included in DG Gel 8 ABO/Rh + Kell card.

4. Antigen expression may be weakened in the red blood cells of persons with leukemia or other malignant diseases.

5. Abnormal concentrations of serum proteins, the presence of infused macromolecular solutions in the serum or plasma may cause non-specific agglutination of the red blood cells.

6. Samples with high-potency antibodies may coat the red blood cells completely, causing spontaneous agglutination.

7. If poorly anti-coagulated plasma or incompletely clotted serum is used, fibrin residues may trap non-agglutinated red blood cells at the top of the gel, appearing as a pinkish or reddish layer. Although the results could be correctly interpreted, in a negative reaction the false appearance of a mixed filed could lead to a misinterpretation. In case of incompletely clotted serum samples, it is recommended to re-clot the serum and repeat the test.

8. A very weak expression or variants of the D antigens may not be detected.
9. On occasions, unagglutinated red blood cells may be retained somewhere in the gel column with the appearance of very minute red dot or fleck. However, this nonspecific retention should not interfere with the interpretation of the result.

SPECIFIC PERFORMANCE CHARACTERISTICS
Grifols DG Gel 8 Blood Grouping Reagents Anti-A, Anti-B, Anti-D meet FDA potency requirements for Blood Grouping Reagents. There is no U.S. standard of potency for the DG Gel 8 Control reagent, which contains no antibody reactivity specific for a blood group antigen. Every lot has been tested against a panel of positive and negative samples for the relevant antigens to assure reactivity and specificity in accordance with FDA requirements. Details of specificity test results submitted to the FDA for release of the product will be furnished upon request.

BIBLIOGRAPHY

PRESENTATION
210384  DG Gel 8 A/B/D  50 Cards

Manufactured by:
Diagnostic Grifols, S.A.
Passeig Fluvial 24 08150 Parets del Vallès (Barcelona), Spain
U.S License No. XXXX

Distributed by:
Novartis Vaccines and Diagnostics, Inc.
Emeryville, CA, USA 94608
Telephone (in U.S.): (800)452-6877
Or: (510)923-3757
Fax: (800)462-3938
Email: emv.cts@novartis.com

Date of last version: April 2013.
SYMBOLS KEY

One or more of these symbols may have been used in the labeling/packaging of this product.

- In vitro diagnostic medical device
- Batch code
- Use by YYYY.MM.DD or YYYY.MM
- Temperature limitations
- Consult instructions for use
- Catalog number
- This way up
- Fragile, handle with care
- Keep dry